BiosimilarsBiosimilars to increase adoption of biologics in Emerging Markets. Past Evidence for the Future.
BiosimilarsAt least 255 pharmaceuticals playing biosimilars. Rise of the "Pharmerging" middle class.
BiosimilarsAnti TNF biosimilars infliximab and etanercept conquer 63% and 44% of the Top 5 EU in under 3 years.
BiosimilarsBiosimilars following same pattern as generics? Neupogen keeps just 6% of EU market after 10 years.
